Bimekizumab response maintenance to 48 weeks in patients with moderate to severe hidradenitis suppurativa: Pooled responder analysis from the phase 3, double-blind, placebo-controlled, randomized clinical trials BE HEARD I & II

Synopsis
- Hidradenitis suppurativa (HS) is a chronic, relapsing, and painful inflammatory skin disease associated with significant comorbidities and poor quality of life.1
- However, treatment options are limited.1
- Bimekizumab (BKZ), a monoclonal immunoglobulin G1 antibody which selectively inhibits interleukin-17A, has demonstrated efficacy in patients with moderate to severe HS.2
- Here, we report maintenance of response through Week 48 for BE HEARD I and II.3,4

Objective
To report maintenance of response over 48 weeks in patients with moderate to severe HS who achieved clinical responses after 16 weeks of BKZ treatment from the phase 3 BE HEARD I & II studies.

Methods
- Data were pooled from BE HEARD I & II.1,2 These randomized, double-blind, placebo- (PBO-) controlled phase 3 studies were comprised of an initial (Weeks 0–16) and a maintenance (Weeks 16–48) treatment period (Figure 1).
- Maintenance of response is reported respectively as the percentage of BKZ-treated patients who achieved ≥50/75/90% HS Clinical Response (HiSCR50/75/90) or b) an abscess and inflammatory nodule (AN) count of 0, 1, or 2 at both Week 16 and Week 48.
- Data are reported as observed cases (OC) throughout; last observation carried forward (LOCF) data are provided in Table 2.

Results
Baseline Characteristics
- Baseline demographics were comparable across treatment arms (Table 1).
- Week 48 Responders
  - Among Week 16 HiSCR50 responders, 88.5–89.6% of patients maintained this response through Week 48, across treatment regimens (Table 2, Figure 2).
  - Among Week 16 HiSCR75 responders, 80.9–88.6% of patients maintained this response through Week 48, across treatment regimens (Table 2, Figure 3).
  - Among Week 16 HiSCR90 responders, 65.2–69.2% of patients maintained this response through Week 48, across treatment regimens (Table 2, Figure 4).
  - Among patients with an AN count of 0, 1, or 2 at Week 16, 82.1%–88.0% of patients maintained this response through Week 48, across treatment regimens (Table 2, Figure 5).

Conclusions
Maintenance of response among Week 16 responders was high across the primary endpoint (HiSCR50) and more stringent clinical outcome measures for BKZ-randomized patients.

Table 1 Baseline characteristics

Table 2 Maintenance of response through Week 48 (OC, LOCF)

Figure 1 Study design

Figure 2 HiSCR50 maintenance of response (OC, LOCF)

Figure 3 HiSCR75 maintenance of response (OC, LOCF)

Figure 4 HiSCR90 maintenance of response (OC, LOCF)

Figure 5 AN count of 0, 1, 2 maintenance of response (OC, LOCF)